Dr. Clay Siegall is the co-founder, and President of Seattle Genetics. Dr. Siegall used innovative ideas, thorough research and drug development in order to find ways to cure patients with cancer. With the help of Dr. Siegall, Seattle Genetics (publically traded on the NASDAQ Market), has capital-raising activities set over $675 million- this includes private and public financings. This company is the leader in what is known as “antibody drug conjugates” (ADC) to fight cancer. ACETRIS was the first product created by the ADC method. It was approved by the FDA in 2011. ACETRIS is available in over 50 countries around the world. Thanks to ADCETRIS, more than 15,000 lymphoma patients have found treatment. This treatment is even being used to help patients with Hodgkin’s lymphoma that may relapse. Along with ADCETRIS, Seattle Genetics is working on other clinical-stage programs. This includes SGN-CD33A for acute myeloid leukemia. Also, SGN-CD19a, is likely to be used for non-Hodgkin lymphoma.
Other cancer-related programs include ALCANZA, ECHELON-1 and ECHELON-2. Seattle Genetics is also making innovating strides toward cytotoxic therapy, or “cell-killing therapy”.
Clay Siegall’s goal is to kill only malignant cells, since chemotherapy can kill healthy cells in the process. Also, malignant cells can build a resistance, making it harder for the cancer to be terminated in the body. The goal is to keep the patient cancer-free, only sacrificing cancerous cells in the process.
Seattle Genetics was founded in 1998 in a suburb known as Bothell, Washington, North of Seattle. Along with serving as President of Seattle Genetics, Dr. Siegall is on the Board of Directors for Ultragenyx Pharmaceutical (since January 2014), Alder Biopharmaceuticals, Inc (Since 2006), and Mirna Therapeutics Inc. (Since 2013). Dr. Siegall has received his Bachelor of Science (Zoology) from the University of Maryland. He received his Ph.D (Genetics) from the George Washington University. Seattle Genetics, the company’s goal is to “make a difference in the life of cancer patients”. The company has over 650 employees.